Vitruvia Medical AG Announces Improved Year-End Financial Results for 2023

Vitruvia Medical AG, based in Anglikon, reported its financial outcomes for the year ended December 31, 2023. The company recorded a significantly reduced post-tax loss of CHF -243,864.40, a sharp improvement from the previous year's loss of CHF -1,095,349.38.

The company's consolidated revenue saw growth, rising to EUR 1,757,724.00 from EUR 1,525,529.00 in the previous year. Additionally, its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITA) turned positive at EUR 61,078.00, compared to a loss of EUR -912,086.00 a year earlier.

Earnings after taxes and amortization of goodwill also marked improvement, totaling EUR -535,435 compared to the previous year's EUR -1,484,556. Overall, 2023 saw substantial recovery in both revenues and earnings metrics reflecting a positive trajectory compared to 2022.

LT technologies, a part of Vitruvia Medical AG's operations, met its sales and profit targets for 2023, with optimistic expectations for continued growth in sales and profits for 2024.